In this book, the authors present a detailed analysis of ARV medicines launched on the market and registered

in the main regulatory agencies, comparing them with the lists of essential medicines in both Brazil and

of the World Health Organization (WHO). The research revealed a number of valuable insights, including the identification of

20 potential ARV drugs for national production and the need for specific public policies for the development of pediatric formulations and the management of drug portfolios.